Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow BJDX
Bluejay Diagnostics, Inc. (BJDX) Altman Z-score
Bluejay Diagnostics, Inc.'s Altman Z-score for fiscal 2022 is −0.90, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2022 | −0.90 | — |
How fiscal 2022’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.75 | — | 0.90 | |
| Retained earnings / total assets | (1.26) | — | −1.76 | |
| EBIT / total assets | (0.69) | — | −2.27 | |
| Market value of equity / total liabilities | 3.68 | — | 2.21 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −0.90 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 2.32 | ||
Z and Z″ put Bluejay Diagnostics, Inc. in different zones: distress zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BJDX Bluejay Diagnostics, Inc. | −0.9× |
| TRIB Trinity Biotech PLC compare | −2.8× |
| ADGM Adagio Medical Holdings, Inc. compare | −7.0× |
| IVF INVO Fertility, Inc compare | −7.6× |
| VVOS Vivos Therapeutics, Inc. compare | −9.1× |
| ICCM IceCure Medical Ltd. compare | −10.0× |
| INBS Intelligent Bio Solutions Inc. compare | −11.4× |
| BIOLQ Biolase, Inc. compare | −12.7× |
| NXL Nexalin Technology, Inc. compare | −26.9× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets